News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Zanidatamab is approved by US FDA based off Herizon BTC01
Nov 24, 2024, 04:47

Zanidatamab is approved by US FDA based off Herizon BTC01

Oncology Brothers shared a post on X:

“Zanidatamab (bispecific antibody against Her2) now US FDA approved for unresectable/metastatic HER2+ biliary tract cancer based off HerizonBTC01 – Single arm Ph2B study, 20 mg/kg IV Q2W – mDoR 14.9mos – mOS 15.5mos – AEs: Diarrhea, EF.”

Zanidatamab

Zanidatamab

More posts featuring Oncology Brothers.

antibody biliary tract Biliary tract cancer cancer diarrhea HER2 HerizonBTC01 metastatic OncoDaily Oncology Oncology Brothers US FDA Zanidatamab
Special Coverage
Science
Sep 4, 2025, 12:51
Siddharth Sreemahadevan: PSMA PET/CT in Staging of Prostate Cancer – Gamechanger or Hype?
Voices
Sep 4, 2025, 12:46
Haig Aghajanian: The End of My Chapter with Capstan
Voices
Sep 4, 2025, 12:37
A Legacy will be Forged Through the New Richard Scolyer Chair in Brain Cancer - Mark Hughes Foundation Centre for Brain Cancer Research
Voices
Sep 4, 2025, 12:26
Bogda Koczwara: Misdiagnoses, Financial Burden and Barriers in Rare Cancer Care in Australia
Voices
Sep 4, 2025, 12:10
Raymond Chan: Cancer Australia’s Vision for An Integrated Cancer Care Navigation System
Voices
Sep 4, 2025, 11:57
Enhancing Patient Understanding of Cancer Treatment Impacts on Quality of Life - Common Sense Oncology
Voices
Sep 4, 2025, 11:39
Lacy Hubbard: Honored to Join the RSOG 11th Annual Scientific Conference
Voices
Sep 4, 2025, 09:26
Kevin Lo: A Touch of Pink for a Powerful Purpose
Science
Sep 4, 2025, 09:19
Elisa De Paolis: NRG1 VUS Network Analysis and Prognostic Role in EGFR-Mutant NSCLC
FDA Approvals
Sep 4, 2025, 09:08
FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC
Voices
Sep 4, 2025, 09:05
What Problems We’re Addressing and How We’re Supporting Children with Cancer - World Child Cancer USA
Insight
Sep 4, 2025, 08:53
Register Now for ASGCR 2025 Select Sessions - NCI Center for Global Health